Clene Inc Dossier
Qualitative Analysis
Business overview
Clene Inc. (NASDAQ: CLNN) is a late clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of clean-surfaced nanotechnology (CSN) therapeutics. The company's proprietary electro-crystal-chemistry platform enables the production of stable, highly concentrated nanocrystal suspensions. Its lead investigational asset is CNM-Au8, an oral suspension of catalytically active gold nanocrystals designed to restore neuronal health and protect mitochondrial function by catalyzing NAD+ metabolism. Clene targets severe neurodegenerative conditions with high unmet medical needs, including amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Parkinson's disease.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the regulatory path for lead drug candidate CNM-Au8 in ALS. Following a successful Type C meeting with the FDA, the company is preparing an NDA submission based on neurofilament light chain (NfL) biomarker reductions and long-term survival data.
Expected impact: Positions CNM-Au8 to potentially become the first disease-modifying nanotherapeutic approved for ALS, transforming Clene into a commercial-stage biopharmaceutical entity.
Securing financial stability through strategic equity offerings and debt restructuring. This includes a $7.0 million underwritten registered direct offering in May 2026 and an amendment to its $10.0 million convertible debt facility to extend maturity to August 2027 and eliminate monthly payments before maturity.
Expected impact: Extends the company's operating runway into the fourth quarter of 2026 and reduces near-term cash burn, allowing focus on regulatory milestones.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Provides non-dilutive funding to support the Expanded Access Program (EAP) for CNM-Au8 in ALS, generating critical long-term safety and biomarker data to support regulatory filings.
Terms: Part of a four-year, $45.1 million NIH grant. Clene entered into a Year 3 subaward agreement with NYU (the prime awardee) for up to $8.0 million covering September 1, 2025, to August 31, 2026, reimbursed monthly based on submitted invoices.
Synapticure serves as an enrolling study site for Clene's ACT-EAP, expanding patient access to CNM-Au8 and accelerating the collection of high-quality clinical data.
Terms: Funded under the NIH-sponsored Expanded Access Program grant.
Collaborating to analyze neurofilament light (NfL) biomarker data from ALS patients, leveraging APST's extensive database to compare findings with Clene's EAP cohorts to support the NDA submission.
Terms: Terms not publicly disclosed.